MAP2K7 and melanoma: Furthermore, the new MEK inhibitor trametinib (GSK1120212) has shown evidence of clinical efficacy against melanoma (Falchook et al., 2012), and has shown survival benefits in phase III trial (Flaherty et al., 2012).